BioSpace News Archive

Relation Therapeutics, a drug development company driven by data science and machine learning, announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.

Sage Therapeutics to Present at Morgan Stanley 18 th Annual Global Healthcare Conference

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorder Data support planned initiation of registrational trial in 2021 BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that Humana Inc. (“Humana”), one of the leading health plans in the U.S., will provide coverage for the Company’s Inspire therapy, effective August 27, 2020. Humana is a national healthcare company that provide

FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting BUFFALO, N.Y., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepte

HPOne and FDS Announce Strategic Partnership to Expand Medicare Education and Enrollment Services to Pharmacies and their Patients

Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional

Promega today launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech. The personal CE system is an integrated DNA analysis instrument that enables life scientists in laboratories of all sizes to perform Sanger sequencing and fragment

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman , Nevro’s Chairman, CEO and President, will present at the following conferences: Wells Fargo 2020 Virtual Healthcare Conference

Mevion Medical Systems and Proton International announced today that they have signed a two-system contract to bring Mevion’s compact proton therapy solution to new centers in locations to be announced in South Texas and the Southeast United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005396/en/ The MEVION S250i Proton Therapy System